Immunome, Inc. (IMNM) is a publicly traded Healthcare sector company. As of May 20, 2026, IMNM trades at $21.47 with a market cap of $2.25B and a P/E ratio of -8.89. IMNM moved +9.59% today. Year to date, IMNM is +9.23%; over the trailing twelve months it is +151.52%. Its 52-week range spans $5.15 to $27.65. Analyst consensus is strong buy with an average price target of $35.17. Rallies surfaces IMNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IMNM financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. IMNM recently traded at $21.47. Market cap is $2.25B. P/E ratio is -8.89. Revenue is $4.01M.
| Metric | Value |
|---|---|
| Price | $21.47 |
| Market Cap | $2.25B |
| P/E Ratio | -8.89 |
| EPS | $-2.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.65 |
| 52-Week Low | $5.15 |
| Volume | 1.14M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.01M |
| Net Income | $-224.59M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.94M | $-212.39M | $-2.43 |
| 2024 | $9.04M | $-292.96M | $-5.00 |
| 2023 | $14.02M | $-106.81M | $-5.38 |
| 2022 | $5.00K | $-36.90M | $-3.09 |
14 analysts cover IMNM: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.17.